Iowa City, IA10 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Iowa City, IA

Find 10 actively recruiting myalgic encephalomyelitis clinical trials in Iowa City, IA. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
2,142
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Iowa City

RecruitingIowa City, IANCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingIowa City, IANCT06679855

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the ...

316 participants
NICHD Neonatal Research Network
View Study Details
RecruitingIowa City, IANCT05655312

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluate...

264 participants
Perspective Therapeutics
View Study Details
RecruitingIowa City, IANCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glo...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingIowa City, IANCT07038200

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)...

200 participants
Avidity Biosciences, Inc.
View Study Details
RecruitingIowa City, IANCT03567889

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of...

186 participants
Philogen S.p.A.
View Study Details
RecruitingIowa City, IANCT04817618

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, r...

98 participants
Novartis Pharmaceuticals
View Study Details
RecruitingIowa City, IANCT05932680

Limited-duration Teclistamab

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria...

75 participants
Abramson Cancer Center at Penn Medicine
View Study Details
RecruitingIowa City, IANCT06194929

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to ...

33 participants
University of Utah
View Study Details
RecruitingIowa City, IANCT05583708

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with ...

18 participants
Weill Medical College of Cornell University
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Iowa City

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 10 myalgic encephalomyelitis clinical trials recruiting participants in Iowa City, IA. These studies are seeking a combined 2,142 participants. Research is being sponsored by Immunocore Ltd, NICHD Neonatal Research Network, Perspective Therapeutics and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Iowa City — FAQ

Are there myalgic encephalomyelitis clinical trials in Iowa City?

Yes, there are 10 myalgic encephalomyelitis clinical trials currently recruiting in Iowa City, IA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Iowa City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you about next steps.

Are clinical trials in Iowa City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Iowa City studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 10 active trials in Iowa City are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov